Skip to main content

""

Ongoing Private
Sector Projects

The following projects are currently being completed by DAS.

Client: Sanofi Pasteur

Research Question/Objectives: The objective of this research is to utilize linked health administrative databases in Ontario to establish the burden of Clostridium difficile (CDI) in Canada’s most populous province. Through the use of descriptive statistics, regression modeling and matched case-control analysis, this study will answer important questions about CDI which are necessary for optimal decision-making regarding prevention and treatment planning. Specifically , the research questions of interest are:

  • To measure the annual incidence of CDI in Ontario, both overall and in acute care hospitals, long-term care facilities, and community-dwelling populations 
  • To determine the complication rates associated with CDI in these populations, compared to control groups with similar demographics and medical history 
  • To estimate the cost of health care utilization associated with CDI in Ontario.

Availability of Results: study in progress


Client: Shoppers Drug Mart

Research Question/Objectives: An average 50% of patients with chronic disease discontinue their medication within the first year. Non-adherence accounts for 5% of hospitalizations and $7-9B in health care costs. This study aims to understand what factors contribute to adherent/non-adherent behaviour, to inform future work examining whether targeted incentives can lead to improved adherence and preventative health management in Ontario for 2016. Over the longer term, there is interest to see whether these incentives translate to improved health outcomes (i.e. lower health care utilization or hospitalizations). The practice of offering incentives is not currently permitted in Ontario. Specifically, the research questions of interest are:

  • Identify the variables associated with medication adherence among the study population. Results will identify risk factors of non-adherence, and will inform inclusion and exclusion criteria for Phase 2
  • Explore the relationship between medication adherence, health outcomes and health care utilization among the study population.

Availability of Results: study in progress


Client: Bristol-Myers Squibb

Research Question/Objectives: The objective of this study is to examine the real-world utilization, clinical outcomes and safety profile of non-vitamin K antagonists (novel oral anticoagulants -NOACs) as compared with those of vitamin K antagonists (VKAs) for the prevention of stroke and systemic embolism in patients with atrial fibrillation (AF). The primary objectives of this study will be to evaluate the outcomes in patients with AF receiving NOACs and VKAs, with respect to: stroke and systemic embolism, major bleeding requiring hospitalization, all-cause mortality, and hospitalizations for all causes. The secondary objectives of this study will be to define the characteristics of OAC users as well as to evaluate the treatment patterns of OACs in the management of AF, and their financial impacts, and to furthermore compare outcomes between warfarin and the NOACs –if feasible. Specifically, the research questions of interest are:

  • What are the characteristics within the Ontario Public Drug Plan of the AF population, including those of OAC users and non-users?
  • What are NOAC- and VKA-use patterns among patients diagnosed with AF for the prevention of strokes and systemic embolism?
  • What are the stroke rates overall and in various subpopulations, in patients with AF on each of the NOACs and warfarin and no anticoagulant?
  • In patients with AF, what is the safety profile of NOACs versus VKA in terms of hospitalization for gastrointestinal (GI) bleeding and other major bleeding?
  • What are the relative hospitalization and mortality risks associated with the exposure of each OAC used in the prevention of stroke and systemic embolism?

Availability of Results: study in progress


Client: imshealth | brogan

Research Question/Objectives: Hypoparathyroidism is a rare disease as noted by NORD and typically is caused by damage to the parathyroid during head and neck surgery. Treatment is chronic and consists of vitamin D and calcium supplements. In contrast to hyperparathyroidism, hypoparathyroidism is not well studied, and only five prevalence studies have been published outside of Canada. This study aims to understand the epidemiology and burden of hypoparathyroidism in Ontario. Specifically, the research questions of interest are:

  • What is the prevalence, incidence, and burden of illness of hypoparathyroidism in Ontario?
  • What treatments are received by hypoparathyroidism patients in Ontario?
  • What are the costs and resource utilization of Ontarians with hypoparathyroidism?

Availability of Results: study in progress


Client: Amgen Canada Inc.

Research Question/Objectives: There are minimal data available in Canada describing the prevalence of Atherosclerotic Cardiovascular Disease (ASCVD) as defined in the Canadian Cardiovascular Society dyslipidemia guidelines, nor are there data on the progression of the disease over time and the association with healthcare utilization. With the recent availability of new non-statin medications to lower low density lipoprotein – Cholesterol (LDL-C levels) and demonstrated improvement in morbidity and mortality outcomes in patients treated with these drugs, there is a need to understand the real-world burden of illness and cost of ASCVD to the Canadian healthcare system. Specifically, the research objectives of interest are::

  • To describe the incidence, prevalence, patient characteristics (including comorbidities), and health resource utilization of patients with ASCVD in Ontario, Canada.
  • To describe the time from first ASCVD event to second event, and subsequent event(s), and/or mortality, if applicable.
  • To describe the type of second and/or subsequent event(s) relative to the type of primary event.

Availability of Results: study in progress



×